(Reuters) – Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer.
(Reporting by Christy Santhosh; Editing by Shailesh Kuber)
US FDA places clinical hold on Iovance’s lung cancer treatment trial
